Mechanisms of hepatic chylomicron remnant clearance

Diabetic Medicine

Volumn 14, Issue SUPPL. 3, 1997, Pages

  Willnow, T E ^a  

^a MAX DELBRÜCK CENTER FOR MOLECULAR MEDICINE   (Germany)

Author keywords

Apo E; Chylomicron remnants; LDL receptor related protein; LDL receptor; Lipoprotein clearance

Indexed keywords

APOLIPOPROTEIN E; CHYLOMICRON; LOW DENSITY LIPOPROTEIN RECEPTOR;

ANIMAL MODEL; ARTICLE; ATHEROGENESIS; ATHEROSCLEROSIS; BINDING SITE; CORONARY ARTERY DISEASE; GENE TARGETING; LIPOPROTEIN METABOLISM; LIVER CELL; LIVER METABOLISM; MOUSE; NONHUMAN; POSTPRANDIAL STATE; RECEPTOR BINDING;

ANIMALS; CARDIOVASCULAR DISEASES; CHYLOMICRONS; GENOTYPE; HEPARAN SULFATE PROTEOGLYCANS; HUMANS; LIVER; MICE; MICE, KNOCKOUT; RECEPTORS, LDL; RISK FACTORS;

EID: 0030785846     PISSN: 07423071     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1096-9136(199708)14:3+3.0.CO;2-9     Document Type: Article

References (34)

1. Karpe F, Steiner G, Uffelman K, Olivecrona T, Hamsten A. Postprandial lipoproteins and progression of coronary atherosclerosis. Atherosclerosis 1994; 106: 83-97.
2. Weintraub MS, Grosskopf I, Rassin T, Miller H, Charach G, Rotmensch HH, et al. Clearance of chylomicron remnants in normolipidaemic patients with coronary artery disease: case control study over three years. Br Med J 1996; 312: 935-939.
3. Mahley RW, Rall SC Jr. Type III hyperlipoproteinemia (dysbetalipoproteinemia): the role of apolipoprotein E in normal and abnormal lipoprotein metabolism. In: Scriver CR, Beaudet AL, Sly WS, Valle D, eds. The Metabolic Basis of Inherited Disease. New York: McGraw-Hill, 1989: 1195-1213.
4. Plump AS, Smith JD, Hayek T, Aalto-Setälä K, Walsh A, Verstuyft JG, et al. Severe hypercholesterolemia and atherosclerosis in apolipoprotein E-deficient mice created by homologous recombination in ES cells. Cell 1992; 71: 343-353.
5. Zhang SH, Reddick RL, Piedrahita JA, Maeda N. Spontaneous hypercholesterolemia and arterial lesions in mice lacking apolipoprotein E. Science 1992; 258: 468-471.
6. Reddick RL, Zhang SH, Maeda N. Atherosclerosis in mice lacking Apo E. Arterioscler Thromb 1994; 14: 141-147.
7. Sowers JR, Sowers PS, Peuler JD. Role of insulin resistance and hyperinsulinemia in development of hypertension and atherosclerosis. J Lab Clin Med 1994; 123: 647-652.
8. Georgopoulos A. Are chylomicron remnants involved in the atherogenesis of insulin-dependent diabetes mellitus? J Lab Clin Med 1994; 123: 640-646.
9. Yamamoto T, Davis CG, Brown MS, Schneider WJ, Casey ML, Goldstein JL, et al. The human LDL receptor: a cysteine-rich protein with multiple Alu sequences in its mRNA. Cell 1984; 39: 27-38.
10. Goldstein JL, Brown MS. Familial hypercholesterolemia. In: Scriver CR, Beaudet AL, Sly WS, Valle D, eds. The Metabolic Basis of Inherited Disease. New York: McGraw-Hill, 1989; 1215-1250.
11. Ishibashi S, Brown MS, Goldstein JL, Gerard RD, Hammer RE, Herz J. Hypercholesterolemia in LDL receptor knock-out mice and its reversal by adenovirus-mediated gene delivery. J Clin Invest 1993; 92: 883-893.
12. Ishibashi S, Goldstein JL, Brown MS, Herz J, Burns DK. Massive xanthomatosis and atherosclerosis in cholesterolfed LDL receptor-negative mice. J Clin Invest 1994; 93: 1885-1893.
13. Rubinsztein DC, Cohen JC, Berger CM, van der Westhuyzen DR, Coetzee GA, Gevers W. Chylomicron remnant clearance from the plasma is normal in familial hypercholesterolemic homozygotes with defined receptor defects. J Clin Invest 1990; 86: 1306-1312.
14. Herz J, Hamann U, Rogne S, Myklebost O, Gausepohl H, Stanley KK. Surface location and high affinity for calcium of a 500-kd liver membrane protein closely related to the LDL-receptor suggest a physiological role as lipoprotein receptor. EMBO J 1988; 7: 4119-4127.
15. Krieger M, Herz J. Structures and functions of multiligand lipoprotein receptors: macrophage scavenger receptors and LDL receptor-related protein (LRP). Annu Rev Biochem 1994; 63: 601-637.
16. Beisiegel U, Weber W, Ihrke G, Herz J, Stanley KK. The LDL-receptor-related protein, LRP, is an apolipoprotein E-binding protein. Nature 1989; 341: 162-164.
17. Kowal RC, Herz J, Goldstein JL, Esser V, Brown MS. Low density lipoprotein receptor-related protein mediates uptake of cholesteryl esters derived from apoprotein E-enriched lipoproteins. Proc Natl Acad Sci USA 1989; 86: 5810-5814.
18. Herz J, Clouthier DE, Hammer RE. LDL receptor-related protein internalizes and degrades uPA/PAI-1 complexes and is essential for embryo implantation. Cell 1992; 71: 411-421.
19. Herz J, Clouthier DE, Hammer RE. Correction: LDL receptor-related protein internalizes and degrades uPAPAI-1 complexes and is essential for embryo implantation. Cell 1992; 73: 428.
20. Willnow TE, Armstrong SA, Hammer RE, Herz J. Functional expression of low density lipoprotein receptor-related protein is controlled by receptor-associated protein in vivo. Proc Natl Acad Sci USA 1995; 92: 4537-4541.
21. 2-macroglobulin receptor and low density lipoprotein receptor-related protein suggests that this molecule is a multifunctional receptor. J Biol Chem 1990; 265: 17401-17404.
22. 2-macroglobulin receptor. FEBS Lett 1990: 276: 151-155.
23. Biemesderfer D, Dekan G, Aronson PS, Farquhar MG. Biosynthesis of the gp330/44-kDa Heymann nephritis antigenic complex: assembly takes place in the ER. Am J Physiol 1993; 264: F1011-F1020.
24. Bu G, Geuze HJ, Strous GJ, Schwartz AL. 39 kDa receptor-associated protein is an ER resident protein and molecular chaperone for LDL receptor-related protein. EMBO J 1995; 14: 2269-2280.
25. 2 ,-macroglobulin receptor. J Biol Chem 1991; 266: 21252-21258.
26. Willnow TE, Rohlmann A, Horton J, Otani H, Braun JR, Hammer RE, Herz J. RAP, a specialized chaperone, prevents ligand-induced ER-retention and degradation of LDL receptor-related receptors. EMBO J 1996; 15: 2632-2639.
27. De Faria E, Fong LG, Komaromy M, Cooper AD. Relative roles of the LDL receptor, the LDL receptor-like protein, and hepatic lipase in chylomicron remnant removal by the liver. J Lipid Res 1996; 37: 197-209.
28. Ishibashi S, Perrey S, Ghen Z, Osuga J, Shimada M, Ohashi K, et al. Role of the low density lipoprotein (LDL) receptor pathway in the metabolism of chylomicron remnants. J Biol Chem 1996; 271: 22422-22427.
29. Herz J, Qui S-Q, Oesterle A, DeSilva HV, Shafi S, Havel RJ. Initial hepatic removal of chylomicron remnants is unaffected but endocytosis is delayed in mice lacking the low density lipoprotein receptor. Proc Natl Acad Sci USA 1993; 92: 4611-4615.
30. Ji Z-S, Brecht WJ, Miranda RD, Hussain MM, Innerarity TL, Mahley RW. Role of heparan sulfate proteoglycans in the binding and uptake of apolipoprotein E-enriched remnant lipoproteins by cultured cells. J Biol Chem 1993; 268: 10160-10167.
31. Ji Z-S, Fazio S, Lee YL, Mahley RW. Secretion-capture role for apolipoprotein E in remnant lipoprotein metabolism involving cell surface heparan sulfate proteoglycans. J Biol Chem 1994; 269: 2764-2772.
32. Hamilton RL, Wong JS, Guo LSS, Krisans S, Havel RJ. Apolipoprotein E localization in rat hepatocytes by immunogold labeling of cryothin sections. J Lipid Res 1990; 31: 1589-1603.
33. Ji Z-S, Lauer SJ, Fazio S, Bensadoun A, Taylor JM, Mahley RW. Enhanced binding and uptake of remnant lipoproteins by hepatic lipase-secreting hepatoma cells in culture. J Biol Chem 1994; 269: 13429-13436.
34. Ji Z-S, Sanan DA, Mahley RW. Intravenous heparinase inhibits remnant lipoprotein clearance from the plasma and uptake by the liver: in vivo role of heparan sulfate proteoglycans. J Lipid Res 1995; 36: 583-592.